WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H330046
CAS#: 1341207-62-2
Description: Pentixafor is a ligand to make gallium Ga 68-pentixafor, a radioconjugate composed of a synthetic, cyclic pentapeptide analog of stromal-cell derived factor-1 (SDF-1 or CXCL12), which is a ligand for chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), that is radiolabeled, via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA), with the radioisotope gallium Ga 68 (Ga68; 68Ga), with potential use for imaging CXCR4-expressing cells upon positron emission tomography (PET)/computed tomography (CT). Upon administration of 68Ga-pentixafor, the pentixafor moiety targets and binds to CXCR4-expressing cancer cells. Upon PET/CT, CXCR4-expressing cancer cells can be visualized and the expression status of the receptor can be assessed. CXCR4, a marker of poorly differentiated cells, is overexpressed on various cancer cells, and plays a key role in tumor growth, progression, invasiveness and metastasi
Hodoodo Cat#: H330046
Name: Pentixafor
CAS#: 1341207-62-2
Chemical Formula: C60H80N14O14
Exact Mass: 1,220.60
Molecular Weight: 1,221.384
Elemental Analysis: C, 59.00; H, 6.60; N, 16.06; O, 18.34
Related CAS #: 1341207-62-2 1342253-77-3 (Gallium) 1345698-96-5 (Ga-68),
Synonym: Pentixafor; Ligand of gallium Ga 68-pentixafor; CPCR4-2; CPCR-4-2; CPCR 4-2; CPCR42; CPCR-42; CPCR 42; BOCLATIXAFORTIDE
IUPAC/Chemical Name: 2,2',2''-(10-(2-((4-((3-((2R,5S,8S,14R)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-1-methyl-8-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)propyl)carbamoyl)benzyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid
InChi Key: OSUJVKAXNLHVRB-HUMWUIFSSA-N
InChi Code: InChI=1S/C60H80N14O14/c1-70-49(9-5-20-63-55(84)43-16-10-40(11-17-43)33-65-51(77)35-71-22-24-72(36-52(78)79)26-28-74(38-54(82)83)29-27-73(25-23-71)37-53(80)81)58(87)68-46(8-4-21-64-60(61)62)57(86)69-47(32-41-12-15-42-6-2-3-7-44(42)30-41)56(85)66-34-50(76)67-48(59(70)88)31-39-13-18-45(75)19-14-39/h2-3,6-7,10-19,30,46-49,75H,4-5,8-9,20-29,31-38H2,1H3,(H,63,84)(H,65,77)(H,66,85)(H,67,76)(H,68,87)(H,69,86)(H,78,79)(H,80,81)(H,82,83)(H4,61,62,64)/t46-,47-,48+,49+/m0/s1
SMILES Code: OC1=CC=C(C[C@@H](NC(CNC([C@H](CC2=CC3=C(C=CC=C3)C=C2)NC4=O)=O)=O)C(N(C)[C@H](CCCNC(C5=CC=C(CNC(CN6CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC6)=O)C=C5)=O)C(N[C@H]4CCCNC(N)=N)=O)=O)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 1,221.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Toczek J, Riou L. Considerations on PET/MR imaging of carotid plaque inflammation with 68Ga-Pentixafor. J Nucl Cardiol. 2020 Sep 10. doi: 10.1007/s12350-020-02354-3. Epub ahead of print. PMID: 32914318.
2: Zhou X, Dierks A, Kertels O, Kircher M, Schirbel A, Samnick S, Buck AK, Knorz S, Böckle D, Scheller L, Messerschmidt J, Barakat M, Kortüm KM, Rasche L, Einsele H, Lapa C. 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. Cancers (Basel). 2020 Aug 18;12(8):2333. doi: 10.3390/cancers12082333. PMID: 32824832; PMCID: PMC7465161.
3: Derlin T, Jaeger B, Jonigk D, Apel R, Freise J, Shin HO, Weiberg D, Warnecke G, Ross TL, Wester HJ, Seeliger B, Welte T, Bengel FM, Prasse A. Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in IPF. Chest. 2020 Aug 18:S0012-3692(20)34229-X. doi: 10.1016/j.chest.2020.08.2043. Epub ahead of print. PMID: 32822674.
4: Pan Q, Luo Y, Qian M. Detection of Residual Tumor With 68Ga-Pentixafor PET/CT in a Patient With Waldenström Macroglobulinemia and Concurrent John Cunningham Virus-Related Progressive Multifocal Leukoencephalopathy. Clin Nucl Med. 2020 Oct;45(10):792-794. doi: 10.1097/RLU.0000000000003250. PMID: 32804761.
5: Pan Q, Luo Y, Zhang Y, Chang L, Li J, Cao X, Li J, Li F. Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG. EJNMMI Res. 2020 Aug 5;10(1):89. doi: 10.1186/s13550-020-00681-7. PMID: 32757068; PMCID: PMC7406627.
6: Osl T, Schmidt A, Schwaiger M, Schottelius M, Wester HJ. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Theranostics. 2020 Jul 9;10(18):8264-8280. doi: 10.7150/thno.45537. PMID: 32724470; PMCID: PMC7381729.
7: Rausch I, Beitzke D, Li X, Pfaff S, Rasul S, Haug AR, Mayerhoefer ME, Hacker M, Beyer T, Cal-González J. Accuracy of PET quantification in [68Ga]Ga-pentixafor PET/MR imaging of carotid plaques. J Nucl Cardiol. 2020 Jul 21. doi: 10.1007/s12350-020-02257-3. Epub ahead of print. PMID: 32696137.
8: Mayerhoefer ME, Haug A, Jäger U, Pichler V, Pfaff S, Wester HJ, Hacker M, Kazianka L, Staber PB. In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. Cancer Immunol Res. 2020 Aug;8(8):984-989. doi: 10.1158/2326-6066.CIR-19-0880. Epub 2020 Jun 24. PMID: 32580942.
9: Herhaus P, Lipkova J, Lammer F, Yakushev I, Vag T, Slotta-Huspenina J, Habringer S, Lapa C, Pukrop T, Hellwig D, Wiestler B, Buck AK, Deckert M, Wester HJ, Bassermann F, Schwaiger M, Weber WA, Menze B, Keller U. CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma. J Nucl Med. 2020 Apr 24:jnumed.120.241703. doi: 10.2967/jnumed.120.241703. Epub ahead of print. PMID: 32332145.
10: Mayerhöfer ME, Haug A. Hybridbildgebung bei Lymphom [Hybrid imaging in lymphoma]. Radiologe. 2020 May;60(5):376-385. German. doi: 10.1007/s00117-020-00676-4. PMID: 32296856.
11: Zhang H, Maeda M, Shindo M, Ko M, Mane M, Grommes C, Weber W, Blasberg R. Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives. Mol Imaging Biol. 2020 Oct;22(5):1184-1196. doi: 10.1007/s11307-020-01480-1. PMID: 32239371; PMCID: PMC7497443.
12: Pan Q, Luo Y, Cao X, Li J, Li F. Pulmonary Cryptococcosis Accidentally Detected by 68Ga-Pentixafor PET/CT in a Patient With Multiple Myeloma. Clin Nucl Med. 2020 May;45(5):423-425. doi: 10.1097/RLU.0000000000003004. PMID: 32209881.
13: Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, Pan Q, Zhu W, Wang X, Yao S, Kreissl MC, Hacker M, Tong A, Huo L, Li X. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2656-2665. doi: 10.1007/s00259-020-04722-0. Epub 2020 Mar 23. PMID: 32206838.
14: Ding J, Tong A, Zhang Y, Wen J, Huo L. Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas. Clin Nucl Med. 2020 Apr;45(4):336-339. doi: 10.1097/RLU.0000000000002946. PMID: 32108693.
15: Spreckelmeyer S, Schulze O, Brenner W. Fully-automated production of [68Ga]Ga-PentixaFor on the module Modular Lab-PharmTracer. EJNMMI Radiopharm Chem. 2020 Feb 27;5(1):8. doi: 10.1186/s41181-020-0091-2. PMID: 32107654; PMCID: PMC7046903.
16: Pan Q, Luo Y, Cao X, Li J, Li F. Posttreated POEMS Syndrome With Concurrent Follicular Lymphoma Revealed by 18F-FDG and 68Ga-Pentixafor PET/CT. Clin Nucl Med. 2020 Mar;45(3):220-222. doi: 10.1097/RLU.0000000000002923. PMID: 31977484.
17: Cui Y, Zhang Y, Ding J, Wang H, Ma X, Wang O, Chang X, Sun H, Huo L, Tong A. A Rare Aldosterone-Producing Adenoma Detected by 68Ga-pentixafor PET- CT: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2019 Nov 29;10:810. doi: 10.3389/fendo.2019.00810. PMID: 31849839; PMCID: PMC6895751.
18: Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):537-546. doi: 10.1007/s00259-019-04605-z. Epub 2019 Nov 27. PMID: 31776631.
19: Borchert T, Beitar L, Langer LBN, Polyak A, Wester HJ, Ross TL, Hilfiker- Kleiner D, Bengel FM, Thackeray JT. Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. J Nucl Cardiol. 2019 Oct 28. doi: 10.1007/s12350-019-01929-z. Epub ahead of print. PMID: 31659697.
20: Kircher M, Tran-Gia J, Kemmer L, Zhang X, Schirbel A, Werner RA, Buck AK, Wester HJ, Hacker M, Lapa C, Li X. Imaging Inflammation in Atherosclerosis with CXCR4-Directed 68Ga-Pentixafor PET/CT: Correlation with 18F-FDG PET/CT. J Nucl Med. 2020 May;61(5):751-756. doi: 10.2967/jnumed.119.234484. Epub 2019 Oct 25. PMID: 31653710.
